+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Myopic choroidal neovascularisation – Use the patient’s motivation


      Karger Kompass Ophthalmologie

      S. Karger AG

      Intravitreal injections, Myopic choroidal neovascularization, Ranibizumab

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Purpose: The aim of this study was to evaluate the 9-year outcome of ranibizumab monotherapy for myopic choroidal neovascularization (mCNV). Methods: This was a retrospective, nonrandomized, multicentric study to evaluate the long-term outcomes of mCNV treated with ranibizumab monotherapy for at least 9 years according to a strict pro re nata regimen. Results: Seventeen eyes of 17 patients (12 women, mean age 57.9 ± 7.7 years) were included. The mean follow-up period was 112.4 ± 3.9 months (range 108–120). The mean difference in best-corrected visual acuity (BCVA) from baseline to the last follow-up was +1.2 ± 15.6 ETDRS letters (p = 0.004, between initial vs. 12 and 24 months). The mean total number of intravitreal injections for each patient was 1.24 ± 1.70 per year (range 2–25). No systemic adverse reactions related to the drug treatment were detected during the 9-year follow-up period. Conclusions: Long-term ranibizumab monotherapy treatment induces unchanged or better BCVA compared to baseline after a 9-year treatment in almost all eyes.

          Related collections

          Author and article information

          Karger Kompass Ophthalmologie
          S. Karger AG
          October 2020
          29 September 2020
          : 6
          : Suppl 1
          : 17-18
          Universitätsmedizin Göttingen, Abteilung für Augenheilkunde, Göttingen, Germany
          Author notes
          *Prof. Dr. Nicolas Feltgen, Universitätsmedizin Göttingen, Abteilung für Augenheilkunde, Robert-Koch-Straße 40, 37075 Göttingen, Germany, nicolas.feltgen@med.uni-goettingen.de
          511332 Kompass Ophthalmol 2020;6(suppl 1):17–18
          © 2020 S. Karger GmbH, Freiburg

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 2
          Knowledge Transfer


          Comment on this article